Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Clinical trial NCT02260986 · COMPLETED
Trial details
- NCT number
- NCT02260986
- Sponsor
- Regeneron Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-09-01
- Primary completion
- 2015-08-01
- Enrollment
- 740
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.